UPEXI, INC. Files 8-K with Regulatory Updates
Ticker: UPXI · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1775194
| Field | Detail |
|---|---|
| Company | Upexi, Inc. (UPXI) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, company-update
TL;DR
UPEXI, INC. filed an 8-K on Jan 23, 2025, covering regulatory disclosures and other events.
AI Summary
UPEXI, INC. (formerly GROVE, INC.) filed an 8-K on January 24, 2025, reporting events as of January 23, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, incorporated in Nevada, is in the Medicinal Chemicals & Botanical Products sector.
Why It Matters
This 8-K filing provides important updates and disclosures from UPEXI, INC. to the SEC, which are crucial for investors to understand the company's current status and any material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting standard disclosures and does not appear to contain significant negative news.
Key Numbers
- 001-40535 — SEC File Number (Identifies the company's filing with the SEC)
- 83-3378978 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- UPEXI, INC. (company) — Registrant
- GROVE, INC. (company) — Former company name
- January 23, 2025 (date) — Date of earliest event reported
- January 24, 2025 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
- Medicinal Chemicals & Botanical Products (industry) — Standard Industrial Classification
FAQ
What specific events are disclosed under 'Other Events' in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the provided text.
What is the primary business of UPEXI, INC. according to its SIC code?
UPEXI, INC. is classified under SIC code 2833, which corresponds to 'Medicinal Chemicals & Botanical Products'.
When did UPEXI, INC. change its name from GROVE, INC.?
The date of the name change from GROVE, INC. to UPEXI, INC. was April 29, 2019.
Where is UPEXI, INC.'s principal executive office located?
The principal executive offices of UPEXI, INC. are located at 3030 N. Rocky Point Drive, Suite 420, Tampa, FL 33607.
What is the fiscal year end for UPEXI, INC.?
The fiscal year end for UPEXI, INC. is June 30.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-24 09:16:50
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 UPXI NASDAQ Indicate by check mar
Filing Documents
- upxi_8k.htm (8-K) — 24KB
- upxi_ex991.htm (EX-99.1) — 9KB
- upxi_ex991img2.jpg (GRAPHIC) — 4KB
- 0001477932-25-000428.txt ( ) — 166KB
- upxi-20250123.xsd (EX-101.SCH) — 6KB
- upxi-20250123_lab.xml (EX-101.LAB) — 15KB
- upxi-20250123_cal.xml (EX-101.CAL) — 1KB
- upxi-20250123_pre.xml (EX-101.PRE) — 9KB
- upxi-20250123_def.xml (EX-101.DEF) — 2KB
- upxi_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
01 Other Events
Item 8.01 Other Events. On January 23, 2025, Upexi, Inc. (the "Company") issued a press release. The Company is establishing a digital currency holding company to invest and capitalize on the opportunities of cryptocurrency including Bitcoin and other coins with high growth potential. Upexi has made an initial investment in Bitcoin and is actively pursuing additional investment opportunities to expand its portfolio through further direct investment into coins, mining, and M&A in the fintech space. A copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in Item 7.01 and Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing. Section 9 – Financial Statements and Exhibits
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Press Release of Upexi, Inc., dated January 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UPEXI, INC. Dated: January 24, 2025 /s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer 3